Explore

Trendline Trendline
Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback
Trendline Trendline
Tiziana Life Sciences Reports Promising Results in Brain Inflammation Reduction for MSA Patients

Tiziana Life Sciences Reports Promising Results in Brain Inflammation Reduction for MSA Patients

Tiziana Life Sciences Reports Promising Results in Brain Inflammation Reduction for MSA Patients
Trendline Trendline
Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback
Trendline Trendline
Functional Peptide Screening Emerges as Key Differentiator in GPCR and Radiopharma Research

Functional Peptide Screening Emerges as Key Differentiator in GPCR and Radiopharma Research

Functional Peptide Screening Emerges as Key Differentiator in GPCR and Radiopharma Research
Trendline Trendline
PureTech to Present Deupirfenidone Program at American Thoracic Society Conference, Aiming to Transform IPF Treatment

PureTech to Present Deupirfenidone Program at American Thoracic Society Conference, Aiming to Transform IPF Treatment

PureTech to Present Deupirfenidone Program at American Thoracic Society Conference, Aiming to Transform IPF Treatment
Trendline Trendline
Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies

Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies

Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies
Trendline Trendline
Degron Therapeutics Secures $40 Million to Advance Molecular Glue Platform in Immunology

Degron Therapeutics Secures $40 Million to Advance Molecular Glue Platform in Immunology

Degron Therapeutics Secures $40 Million to Advance Molecular Glue Platform in Immunology
Trendline Trendline
Degron Therapeutics Secures $40 Million to Advance Molecular Glue Degrader Development

Degron Therapeutics Secures $40 Million to Advance Molecular Glue Degrader Development

Degron Therapeutics Secures $40 Million to Advance Molecular Glue Degrader Development
Trendline Trendline
MacroGenics Extends Cash Runway to 2028 Through Asset Monetization

MacroGenics Extends Cash Runway to 2028 Through Asset Monetization

MacroGenics Extends Cash Runway to 2028 Through Asset Monetization
Trendline Trendline
Creatv Bio Opens CLIA-Certified Laboratory to Enhance Oncology Drug Development

Creatv Bio Opens CLIA-Certified Laboratory to Enhance Oncology Drug Development

Creatv Bio Opens CLIA-Certified Laboratory to Enhance Oncology Drug Development
Trendline Trendline
Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges

Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges

Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges
Trendline Trendline
Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases

Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases

Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases